Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor

Abstract Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5α-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum , can inhibit prostate cancer cell growth and block osteoclastogenesis.